Opinion|Videos|July 11, 2024
Exploring Biomarker Testing and Personalized Treatments in Breast Cancer
William J. Gradishar, MD, analyzes current guidelines for identifying targetable mutations in breast cancer, explores strategies to enhance biomarker testing for mutations like PIK3CA or AKT1, and anticipates the growing influence of personalized medicine on the future of breast cancer treatment.
Advertisement
Episodes in this series
- What are the current guidelines for testing for targetable mutations in breast cancer, and how widely are they followed in clinical practice? How can biomarker testing for targetable mutations, such as PIK3CA or AKT1, be improved or streamlined?
- How accessible are these biomarker tests in community oncology?
- How is personalized medicine expected to impact the future use of targeted therapies (such as the PI3K pathway inhibitors) in breast cancer? What developments are needed to fully realize its potential?
Advertisement
Related to this article
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
Early-Onset Cancers Often Found Late as Screening Gaps Persist
3
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
4
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
5